Abstract
Ischaemic stroke does not occur at random hours. Onset clusters in the morning, and several physiological correlates of that pattern are well described: an endogenous circadian peak in circulating plasminogen activator inhibitor-1, platelets that aggregate more readily in the hours after rising, and the morning surge in blood pressure. What remains unsettled is whether the hour of onset also influences how quickly brain tissue is lost and how well it responds to treatment. This critical narrative review draws together molecular, experimental and clinical evidence and organises it as a Three-Clock Model: a trigger clock that sets when vessels occlude, a tissue clock that governs the pace of infarct growth, and a treatment clock that modulates the response to reperfusion and to adjunctive or neuroprotective therapy. Human cohorts have reported larger ischaemic cores and faster infarct growth after night-time onset or during night-time interhospital transfer, the latter measured directly with serial diffusion-weighted imaging, and time-of-day differences in thrombectomy outcome, but these associations are vulnerable to confounding by uncertain onset times, out-of-hours care and the gap between clock time and internal circadian phase. In rodents, three neuroprotective strategies reduced infarction when given during the animals’ inactive phase but not during the active phase, a mismatch that may have contributed to failed translation; other experiments disagree about which phase is more damaging. Large pragmatic trials of bedtime antihypertensive dosing have been neutral. We propose a ten-item CHRONO-STROKE minimum reporting dataset, which is author-proposed and unvalidated and intended to supplement existing consensus data elements, a clock-time-stratified design for trials of adjunctive therapy, and five testable predictions, as a means of establishing whether circadian biology deserves a place in acute stroke decision-making.